
SeaSpine Holdings Corporation SPNE
Quarterly report 2022-Q3
added 11-03-2022
SeaSpine Holdings Corporation Total Assets 2011-2026 | SPNE
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets SeaSpine Holdings Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 377 M | 214 M | 142 M | 172 M | 134 M | 147 M | 176 M | 140 M | 153 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 377 M | 134 M | 184 M |
Quarterly Total Assets SeaSpine Holdings Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 374 M | - | 380 M | 377 M | 390 M | 400 M | 230 M | 214 M | 214 M | 214 M | 214 M | 142 M | 142 M | 142 M | 142 M | 172 M | 172 M | 172 M | 172 M | 134 M | 134 M | 134 M | 134 M | 147 M | 147 M | 147 M | 147 M | 176 M | 176 M | 176 M | 176 M | 140 M | 140 M | 140 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 400 M | 134 M | 197 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Bruker Corporation
BRKR
|
5.81 B | - | - | $ 5.81 K | ||
|
Align Technology
ALGN
|
6.21 B | $ 185.02 | -0.81 % | $ 13.9 B | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
188 M | - | 37.08 % | $ 85.7 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
AdaptHealth Corp.
AHCO
|
4.32 B | $ 12.58 | -0.55 % | $ 1.7 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
Cytosorbents Corporation
CTSO
|
44.2 M | $ 0.61 | 3.18 % | $ 38 M | ||
|
EDAP TMS S.A.
EDAP
|
86.1 M | $ 3.59 | 1.99 % | $ 134 M | ||
|
LENSAR
LNSR
|
71.4 M | $ 5.8 | -7.2 % | $ 69.4 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 63.42 | -1.84 % | $ 93.9 B | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | ||
|
Eargo
EAR
|
132 M | - | - | $ 10.2 M | ||
|
ClearPoint Neuro
CLPT
|
97.7 M | $ 10.5 | 0.38 % | $ 297 M | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
53.8 M | $ 25.39 | -1.24 % | $ 215 M | ||
|
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
Sintx Technologies
SINT
|
9.51 M | $ 2.68 | -2.19 % | $ 7.43 M | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
Stryker Corporation
SYK
|
47.8 B | $ 338.38 | -0.87 % | $ 129 B | ||
|
OrthoPediatrics Corp.
KIDS
|
509 M | $ 16.53 | -7.39 % | $ 388 M | ||
|
Tactile Systems Technology
TCMD
|
274 M | $ 25.13 | -0.87 % | $ 575 M | ||
|
Globus Medical
GMED
|
5.3 B | $ 92.76 | -1.89 % | $ 12.5 B | ||
|
TELA Bio
TELA
|
81.4 M | $ 0.73 | 11.88 % | $ 34.3 M | ||
|
Helius Medical Technologies
HSDT
|
7.69 M | $ 2.06 | 6.19 % | $ 1.25 M | ||
|
Butterfly Network
BFLY
|
256 M | $ 5.29 | 8.74 % | $ 1.12 B | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
Tandem Diabetes Care
TNDM
|
881 M | $ 20.09 | -2.76 % | $ 1.37 B | ||
|
Inogen
INGN
|
299 M | $ 6.59 | 6.29 % | $ 175 M | ||
|
IRIDEX Corporation
IRIX
|
29.2 M | $ 1.04 | - | $ 17.6 M | ||
|
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
124 M | $ 10.83 | -1.46 % | $ 388 M | ||
|
Inspire Medical Systems
INSP
|
907 M | $ 56.45 | -0.34 % | $ 1.66 B | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 37.91 | -3.88 % | $ 1.18 B | ||
|
LivaNova PLC
LIVN
|
2.61 B | $ 65.01 | -0.2 % | $ 3.55 B | ||
|
Integer Holdings Corporation
ITGR
|
3.41 B | $ 88.37 | 0.49 % | $ 3.07 B |